Company Filing History:

19 out of 1,858

Takeda Chemical Industries, Inc.

patents

2 out of 1,177

Takeda Pharmaceutical Company Limited

patents

1 out of 228

Senju Pharmaceutical Co., Ltd.

patents

Years Active: 1980-2007

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7256204 - Amine compounds, their production and use (2007-08-14),

2. 7115750 - Melanin concentrating hormone antagonist (2006-10-03),

3. 6930104 - Heterocyclic derivatives (2005-08-16),

4. 6784314 - Process for producing amine derivatives (2004-08-31),

5. 6613805 - Amine compounds, their production and use (2003-09-02),

6. 6586475 - &bgr;-amyloid protein production/secretion inhibitors (2003-07-01),

7. 6329389 - Amine compounds, their production and use (2001-12-11),

8. 6326369 - Bicyclic quinone compounds, their production and use (2001-12-04),

9. 6310107 - Amine compounds, their production and use as amyloid-&bgr; production inhibitors (2001-10-30),

10. 5891916 - Aromatic hydroxamix acid compounds, their production and use (1999-04-06),

11. 5804601 - Aromatic hydroxamic acid compounds, their production and use (1998-09-08),

12. 5665769 - Pharmaceutical composition for preventing and treating retinal diseases (1997-09-09),

13. 5654296 - Condensed heterocyclic compounds, their production and use (1997-08-05),

14. 5633248 - Amine compounds, their production and use (1997-05-27),

15. 5607939 - Condensed heterocyclic compounds, their production and use (1997-03-04),

Title: **Kaneyoshi Kato: Innovator in Pharmaceutical Compounds**

Introduction

Kaneyoshi Kato, based in Kawanishi, Japan, is a distinguished inventor with a remarkable portfolio of 22 patents. His innovative contributions primarily focus on pharmaceutical compounds that address critical health issues, particularly in the field of neurodegenerative diseases.

Latest Patents

Kato's latest patents include novel amine compounds demonstrated to inhibit the production and secretion of amyloid-β proteins, which are implicated in neurodegenerative diseases. The patent describes a complex compound structure with various substituents that enhance its therapeutic efficacy. Additionally, he has developed a melanin-concentrating hormone antagonist, designed to target specific cyclic groups for potential medical applications. These advancements showcase Kato's commitment to advancing pharmaceutical science.

Career Highlights

Throughout his career, Kaneyoshi Kato has made significant contributions while working for esteemed organizations such as Takeda Chemical Industries, Inc. and Takeda Pharmaceutical Company Limited. His work at these institutions has been pivotal in the development of innovative treatments that improve patient outcomes.

Collaborations

Kato has collaborated with notable colleagues, including Jun Terauchi and Mitsuru Kakihana, showcasing the importance of teamwork and shared expertise in the field of research and development. These collaborations have likely contributed to the success and impact of his various patents.

Conclusion

In summary, Kaneyoshi Kato stands out as a prominent figure in the field of pharmaceutical innovations. His extensive patent portfolio and significant contributions to major pharmaceutical companies underline the critical role he plays in developing therapeutic solutions for complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.